Bristol-Myers Squibb remains a Buy with strong dividend and growth outlook despite recent market pressure

Bristol-Myers Squibb (BMY) is recommended as a Buy due to its high dividend yield and strong free cash flow despite recent stock selling pressure. The company's Growth Portfolio drove a 16% year-over-year sales increase, offsetting declines in its Legacy Portfolio. It projects 2026 revenues between $46 billion and $47.5 billion with earnings per share of $6.05 to $6.35. Technical analysis shows support in the mid-$50 range and potential upside to $85 if resistance at $63 is surpassed. Key risks include the expiration of the Eliquis patent and pipeline execution, but recent earnings upgrades and strong cash flow support a positive outlook.